Article

Evaluación de la calidad de la asistencia al paciente diabético en América Latina

Revista Panamericana de Salud Pública 01/2001;
Source: DOAJ

ABSTRACT Objetivos. Hacer un diagnóstico preliminar de la calidad de la atención que reciben las personas con diabetes (DM) en centros tributarios de la red QUALIDIAB y analizar el potencial de esta información y la importancia de la expansión de la red en América Latina y el Caribe. Métodos. Se analizaron 13 513 registros provenientes de centros de atención del subsector público y privado de salud y de la Seguridad Social de Argentina, Brasil, Chile, Colombia, Paraguay y Uruguay (red QUALIDIAB). Se utilizaron indicadores de la calidad de la atención basados en valores de referencia internacionales, una planilla de registro de parámetros clínicos, bioquímicos y terapéuticos y de la tasa de uso de elementos diagnósticos y terapéuticos, un programa para cargar los datos y otro para su análisis estadístico. Resultados. La diabetes tenía una duración < 5 años en alrededor de la mitad de las personas con DM de tipo 1 (DM1) y de tipo 2 (DM2) registradas. El 24% de las personas con DM1 y el 15 % con DM2 tenían glucemias < 4,4 mmol/L, mientras que el 41% con DM1 y el 57% con DM2 tenían glucemias > 7,7 mmol/L. La frecuencia de la asociación de la DM2 con otros factores de riesgo cardiovascular (FRCV) fue la siguiente: sobrepeso/obesidad, 59%; hipertensión, 60%; colesterol total > 5,5 mmol/L, 53%; colesterol de las lipoproteínas de alta densidad < 1 mmol/L, 32%; triglicéridos > 1,7 mmol/L, 45%; tabaquismo 13%. El 20% de las personas con DM1 tenían un índice de masa corporal < 19 kg/m² que probablemente refleje un deficiente control metabólico e hipoinsulinización. La verificación sistemática de indicadores del control metabólico y la detección de FRCV y de complicaciones crónicas de la DM fueron deficientes en el 3 al 75% de los casos. Según los indicadores de educación terapéutica, solo la mitad o la cuarta parte de los participantes podrían desempeñar un papel activo y eficaz en el control y tratamiento de su DM. El 50% de las personas con DM1 son tratadas con combinación de insulinas (NPH + corriente), administrada en dos inyecciones diarias en el 43% de los casos. El 5 y el 9% de los pacientes reciben, respectivamente, 1 y > 3 inyecciones diarias de insulina. El 13% de las personas con DM2 tratan su enfermedad solo con dieta y el 14% solo con insulina. Entre los pacientes tratados con fármacos, los hipoglucemiantes orales más utilizados como monoterapia fueron las sulfonilureas (33%), seguidas por las biguanidas (9%) y su administración combinada (14%). Menos de la mitad de las personas con diabetes reciben farmacoterapia para tratar los FRCV asociados. La frecuencia de las complicaciones microangiopáticas y macroangiopáticas aumentó con la antigüedad de la enfermedad, verificándose los incrementos máximos en la insuficiencia renal y en las amputaciones (alrededor de 7 veces) y los menores en la neuropatía periférica (2 veces) y los accidentes cerebrovasculares (1,6 veces). Conclusiones. Estos resultados demuestran la necesidad de mejorar la calidad de la atención a los pacientes diabéticos y que QUALIDIAB puede ser el instrumento idóneo para ello en América Latina y el Caribe. La ampliación de la Red QUALIDIAB contribuirá a establecer un diagnóstico más preciso de la calidad de dicha atención en la Región y facilitará la implementación de intervenciones destinadas a optimizarla, mejorando así la calidad de vida de quienes la padecen y disminuyendo simultáneamente el costo socioeconómico de la enfermedad.

0 Bookmarks
 · 
104 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Structured diabetes care programs in Argentina are scarce and do not inform about their cost using micro costing techniques. Aim: To estimate the incremental costs of a health care program for type 2 diabetes without complications implemented at sub-national level in Argentina during 2005. Methods: United Kingdom Prospective Diabetes Study and Latin American Diabetes Association guidelines were used to identify which resources should be part of a diabetes program to implement in two Argentinean provinces – Córdoba and Misiones – with high and low socioeconomic characteristics, respectively. A micro costing approach was used to estimate costs from the perspective of a public health payer, taking a province without diabetes program as a comparative scenario. Probabilistic sensitivity analysis following Monte Carlo simulation was used to determine the number of visits and practices, probability of insulin treatment, combination therapy for hypertension, annual number of test strips and unit cost of all resources used. Results: The main component of the annual incremental cost per patient in both provinces was self-monitoring blood glucose (~50%), followed by treatment of diabetes, dyslipidemia and hypertension. The lowest cost corresponded to human resources (<5%). The annual incremental cost per patient was 32% higher in Córdoba due to the pharmacological treatment of diabetes (> 90%). Discussion: This study provides original evidence for Argentina that could facilitate the development and further evaluation of diabetes programs and resource use optimization in the public health care subsector in other provinces/ countries with comparable socioeconomic and health care settings.
    Primary Health Care: Open Access. 12/2011; 1(1).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review presents data on end-stage renal disease (ESRD) due to diabetes (ESRD-DM) from populations of several racial/ethnic groups and regions; it also identifies factors that may explain differences in risk of ESRD-DM among these groups. Diabetes is a major cause of ESRD in several developed countries, including the United States, England, and Australia. However, in these countries, the incidence is much higher for some groups, such as Blacks and Native Americans in the United States, Blacks and Indo-Asians in England, and indigenous populations in Australia. Despite the worldwide increase in the prevalence of diabetes, in some regions such as South Africa and Brazil, the rates of ESRD attributed to hypertension and glomerulonephritis are even higher than rates attributed to diabetes. High prevalence of accelerated/ malignant hypertension and infection-related glomerulonephritis in addition to a higher risk of early death from diabetes might partially explain the predominance of ESRD attributed to hypertensive nephropathy and glomerulonephitis in South Africa and Brazil. These data call attention to the need to develop more effective strategies to prevent type 2 diabetes and thereby reduce the racial/ethnic gap in ESRD-DM. A greater emphasis on hypertension and diabetes control, particularly in racially and economically disadvantaged populations, is also necessary.
    Ethnicity & disease 02/2009; 19(1 Suppl 1):S1-47-51. · 1.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is an expensive disease in Argentina as well as worldwide, and its prevalence is continuously rising affecting the quality of life of people with the disease and their life expectancy. It also imposes a heavy burden to the national health care budget and on the economy in the form of productivity losses. To review and discuss a) the reported evidence on diabetes prevalence, the degree of control, the cost of care and outcomes, b) available strategies to decrease the health and economic disease burden, and c) how the disease fits in the Argentinian health care system and policy. Finally, to propose evidence-based policy options to reduce the burden of diabetes, both from an epidemiological as well as an economic perspective, on the Argentinian society. The evidence presented is expected to help the local authorities to develop and implement effective diabetes care programmes.MethodologyA comprehensive literature review was performed using databases such as MEDLINE, EMBASE and LILACS (Latin American and Caribbean Health Sciences). Literature published from 1980 to 2011 was included. This information was complemented with grey literature, including data from national and provincial official sources, personal communications and contacts with health authorities and diabetes experts in Argentina. Overall diabetes prevalence increased from 8.4% in 2005 to 9.6% 2009 at national level. In 2009, diabetes was the seventh leading cause of death with a mortality rate of 19.2 per 100,000 inhabitants, and it accounted for 1,328,802 DALYs lost in the adult population, mainly affecting women aged over fifty. The per capita hospitalisation cost for people with diabetes was significantly higher than for people without the disease, US$ 1,628 vs. US$ 833 in 2004. Evidence shows that implementation of combined educative interventions improved quality of care and outcomes, decreased treatment costs and optimised the use of economic resources. Based on the evidence reviewed, we believe that the implementation of structured health care programmes including diabetes education at every level, could improve quality of care as well as its clinical, metabolic and economic outcomes. If implemented across the country, these programmes could decrease the disease burden and optimise the use of human and economic resources.
    Globalization and Health 10/2013; 9(1):54. · 1.49 Impact Factor

Full-text (2 Sources)

View
1 Download
Available from
Jul 30, 2014